|
Market Closed -
Nasdaq
04:00:00 2026-09-29 pm EDT
|
5-day change | 1st Jan Change | ||
| 186.14 USD | -4.00% |
|
-8.35% | +1.92% |
| Sep. 29 | Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating | MT |
| Sep. 25 | Axsome's Auvelity Continues Positive Launch Trend, Mizuho Says | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- AXSM Stock
- Consensus Axsome Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
